Development of a novel vaccine carrier for the next-generation influenza universal vaccine

• Project/Area Number: 23590550
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Virology
• Research Institution: Saitama Medical University
• Principal Investigator: MATSUI Masanori 埼玉医科大学, 医学部, 准教授 (50199741)
• Co-Investigator(Kenkyū-buntansha): KAWANO Masaaki 埼玉医科大学, 医学部, 助教 (30447528)
• Co-Investigator(Renkei-kenkyūsha): HANDA Hiroshi 東京医科大学, 医学部, 特任教授 (80107432)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: ワクチン / 感染防御 / ウイルス様粒子 / SV40 / ナノキャリア / 細胞傷害性T細胞 / HLA class I / インフルエンザウイルス / SV40ウイルス様粒子 / HLA-A2

Research Abstract

Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efficiency. However, it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We constructed chimeric SV40-VLPs carrying an HLA-A*02:01-restricted, cytotoxic T lymphocyte (CTL) epitope derived from influenza A virus. HLA-A*02:01-transgenic mice were then immunized with the chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced influenza-specific CTLs and heterosubtypic protection against influenza A viruses without the need of adjuvants. In addition, immunization with the chimeric SV40-VLPs generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.

Research Products

• [Journal Article] Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants (2014)
  • Author(s): M.-A. Kawano, K. Morikawa, T. Suda, N. Ohno, S. Matsushita, T. Akatsuka, H. Handa, M. Matsui
  • Journal Title: Virology Volume: 448 Pages: 159-167
  • DOI: 10.1016/j.virol.2013.10.010
  • Peer Reviewed
• [Journal Article] SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. (2013)
  • Author(s): Kawano, M., M. Matsui, and H. Handa.
  • Journal Title: Expert Rev. Vaccines Volume: 12 Issue: 2 Pages: 199-210
  • DOI: 10.1586/erv.12.149
  • Peer Reviewed
• [Journal Article] Viral protein-coating of magnetic nanoparticles using simian virus 40 VP1 (2013)
  • Author(s): T. Enomoto, M.-A. Kawano, H. Fukuda, W. Sawada, T. Inoue, K. C. Haw, Y. Kita, S. Sakamoto, Y. Yamaguchi, T. Imai, M. Hatakeyama, S. Saito, A. Sandhu, M. Matsui, I. Aoki, H. Handa
  • Journal Title: J. Biotechnol. Volume: 167 Issue: 1 Pages: 8-15
  • DOI: 10.1016/j.jbiotec.2013.06.005
  • Peer Reviewed
• [Journal Article] インフルエンザウイルス特異的CTLの誘導を増強するプラットフォームの開発 (2012)
  • Author(s): 川野雅章、松井政則、禾泰壽,半田宏
  • Journal Title: 埼玉医科大学雑誌 Volume: 第39巻第1号 Pages: 9-13
• [Journal Article] インフルエンザウイルス特異的CTL の誘導を増強する プラットフォームの開発 (2012)
  • Author(s): 川野 雅章、松井 政則、禾 泰壽，半田 宏
  • Journal Title: 埼玉医科大学雑誌 Volume: 39 Pages: 9-13
• [Journal Article] The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that proivde potent protection from influenza A virus. (2011)
  • Author(s): Suda, T., M. Kawano, Y. Nogi, N. Ohno, T. Akatsuka, and M. Matsui.
  • Journal Title: Antiviral Res. Volume: 91 Issue: 3 Pages: 252-258
  • DOI: 10.1016/j.antiviral.2011.06.008
  • Peer Reviewed
• [Journal Article] Local expression of IL-27 ameliorates collagen induced arthritis. (2011)
  • Author(s): Pickens, S. R., N. D. Chamberlain, M. V. Volin, A. M. Mandelin II, H. Agrawal, M. Matsui, T. Yoshimoto, and S. Shahrara.
  • Journal Title: Arthritis Rheum. Volume: 63 Issue: 8 Pages: 2289-2298
  • DOI: 10.1002/art.30324
  • Peer Reviewed
• [Presentation] Development of a CTL-based vaccine carrier with self-adjuvant properties using simian virus 40 virus-like particles (2013)
  • Author(s): 川野雅章、松井政則他
  • Organizer: 第42回日本免疫学会
  • Place of Presentation: 幕張メッセ(千葉)
• [Presentation] ウイルス特異的CTLの誘導を増強するプラットフォームの開発 (2013)
  • Author(s): 川野雅章、松井政則他
  • Organizer: 第11回RCGMフロンティアシンポジウム
  • Place of Presentation: 埼玉医大ゲノム医学研究センター
• [Presentation] Development of a CTL-based vaccine carrier with self-adjuvant properties using simian virus 40 virus-like particles (2013)
  • Author(s): Kawano, M., K. Morikawa, T. Suda, N. Ohno, S. Matsushita, T. Akatsuka, H. Handa, and M. Matsui.
  • Organizer: 第42回日本免疫学会
  • Place of Presentation: 幕張メッセ（千葉）
• [Presentation] ウイルス特異的CTLの誘導を増強するプラットフォームの開発 (2013)
  • Author(s): 川野雅章、松下祥、赤塚俊隆、半田宏、松井政則
  • Organizer: 第11回RCGMフロンティアシンポジウム
  • Place of Presentation: 埼玉医大 ゲノム医学研究センター
• [Presentation] Chimeric VP1 of Simian Virus 40 induces IL-12 production from DC, facilitating CTL induction against an inserted CTL epitope within the VP1 (2012)
  • Author(s): 川野雅章、松井政則他
  • Organizer: 第41回日本免疫学会
  • Place of Presentation: 神戸国際会議場(神戸)
• [Presentation] Chimeric VP1 of Simian Virus 40 induces IL-12 production from DC, facilitating CTL induction against an inserted CTL epitope within the VP1. (2012)
  • Author(s): Kawano, M., T. Suda, S. Matsushita, T. Akatsuka, H. Handa, and M. Matsui.
  • Organizer: 第41回 日本免疫学会
  • Place of Presentation: 神戸国際会議場 神戸
• [Presentation] The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that proivde potent protection from influenza A virus (2011)
  • Author(s): 川野雅章、松井政則他
  • Organizer: 第40回日本免疫学会
  • Place of Presentation: 千葉
• [Presentation] Development of a novel platform for CTL-based influenza vaccine using virus-like particles of Simian Virus 40 (2011)
  • Author(s): 川野雅章、松井政則他
  • Organizer: 第59回日本ウイルス学会、国際ウイルス学会
  • Place of Presentation: 札幌
• [Presentation] Development of a novel platform for CTL-based influenza vaccine using virus-like particles of Simian Virus 40 (2011)
  • Author(s): Kawano, M., T. Suda, T. Akatsuka, H. Handa, and M. Matsui
  • Organizer: 第59回 日本ウイルス学会、国際ウイルス学会
  • Place of Presentation: 札幌コンベンションセンター（札幌）
• [Presentation] The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that proivde potent protection from influenza A virus. (2011)
  • Author(s): Kawano, M., T. Suda, N. Ohno, T. Akatsuka, and M. Matsui.
  • Organizer: 第40回 日本免疫学会
  • Place of Presentation: 幕張メッセ（千葉）
• [Book] SV40 virus-like particles as an effective delivery system and a vaccine platform, Future Medicine, Chapter 6 (2014)
  • Author(s): Kawano, M., M. Matsui, and H. Handa
  • Publisher: E-Book
• [Book] Future Medicine: SV40 virus-like particles as an effective delivery system and a vaccine platform (2014)
  • Author(s): Kawano, M., M. Matsui, and H. Handa.
  • Total Pages: 16
  • Publisher: E-Book (WWW.futuremedicine.com）
• [Patent(Industrial Property Rights)] 細胞傷害性T細胞誘導剤 (2012)
  • Inventor(s): 半 田宏、川 野雅章、松井政則
  • Industrial Property Rights Holder: 半 田宏、川 野雅章、松井政則
  • Industrial Property Rights Type: 特許
  • Filing Date: 2012-04-24
  • Overseas
• [Patent(Industrial Property Rights)] 細胞傷害性T細胞誘導剤 (2012)
  • Inventor(s): 半田宏、川野雅章、松井政則
  • Industrial Property Rights Holder: 半田宏、川野雅章、松井政則
  • Industrial Property Rights Type: 特許
  • Filing Date: 2012-04-24
  • Overseas
• [Patent(Industrial Property Rights)] 細胞傷害性T細胞誘導剤 (2011)
  • Inventor(s): 半 田宏、川 野雅章、松井政則
  • Industrial Property Rights Holder: 半 田宏、川 野雅章、松井政則
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2011-107874
  • Filing Date: 2011-05-13
  • Overseas
• [Patent(Industrial Property Rights)] 細胞傷害性T細胞誘導剤 (2011)
  • Inventor(s): 半田宏、川野雅章、松井政則
  • Industrial Property Rights Holder: 半田宏、川野雅章、松井政則
  • Industrial Property Number: 2011-107874
  • Filing Date: 2011